Luc Furic

7.3k total citations
48 papers, 3.0k citations indexed

About

Luc Furic is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Luc Furic has authored 48 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 16 papers in Pulmonary and Respiratory Medicine and 10 papers in Oncology. Recurrent topics in Luc Furic's work include Prostate Cancer Treatment and Research (15 papers), PI3K/AKT/mTOR signaling in cancer (11 papers) and RNA Research and Splicing (10 papers). Luc Furic is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), PI3K/AKT/mTOR signaling in cancer (11 papers) and RNA Research and Splicing (10 papers). Luc Furic collaborates with scholars based in Australia, Canada and United States. Luc Furic's co-authors include Luc DesGroseillers, Yoon Ki Kim, Lynne E. Maquat, Ola Larsson, Ivan Topisirović, Nahum Sonenberg, Nathaniel Robichaud, Richard J. Rebello, Michaël Pollak and Liwei Rong and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Luc Furic

47 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luc Furic Australia 28 2.4k 465 341 328 257 48 3.0k
Andrew C. Hsieh United States 23 2.6k 1.1× 553 1.2× 568 1.7× 423 1.3× 271 1.1× 70 3.6k
Jasper Mullenders Netherlands 17 2.0k 0.9× 440 0.9× 651 1.9× 204 0.6× 192 0.7× 25 2.7k
Gong‐Hong Wei China 23 2.3k 1.0× 520 1.1× 270 0.8× 358 1.1× 236 0.9× 75 3.0k
Christian Touriol France 30 1.8k 0.8× 389 0.8× 424 1.2× 248 0.8× 228 0.9× 46 2.5k
Jakob Lovén United States 15 2.5k 1.1× 636 1.4× 435 1.3× 113 0.3× 231 0.9× 17 3.1k
Joseph M. Amann United States 28 1.8k 0.8× 426 0.9× 825 2.4× 605 1.8× 173 0.7× 53 2.7k
David Tulasne France 32 1.3k 0.6× 271 0.6× 451 1.3× 436 1.3× 306 1.2× 73 2.4k
Markus E. Diefenbacher Germany 23 1.4k 0.6× 296 0.6× 567 1.7× 151 0.5× 186 0.7× 42 1.9k
Jianfei Qi United States 28 1.9k 0.8× 563 1.2× 615 1.8× 503 1.5× 178 0.7× 61 2.5k
Long‐Yuan Li Taiwan 29 2.5k 1.1× 622 1.3× 976 2.9× 283 0.9× 313 1.2× 79 3.5k

Countries citing papers authored by Luc Furic

Since Specialization
Citations

This map shows the geographic impact of Luc Furic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luc Furic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luc Furic more than expected).

Fields of papers citing papers by Luc Furic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luc Furic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luc Furic. The network helps show where Luc Furic may publish in the future.

Co-authorship network of co-authors of Luc Furic

This figure shows the co-authorship network connecting the top 25 collaborators of Luc Furic. A scholar is included among the top collaborators of Luc Furic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luc Furic. Luc Furic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferreira, Rita, Katherine M. Hannan, Kostya I. Panov, et al.. (2024). Abstract PR004: Second generation RNA Polymerase I inhibitor PMR-116 targets ribsomal RNA synthesis to potently treat a broad spectrum of malignancies. Molecular Cancer Therapeutics. 23(11_Supplement). PR004–PR004. 1 indexed citations
2.
Bai, Yuchen, Carolin Götz, Zixuan Zhao, et al.. (2023). YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells. Nature Communications. 14(1). 1591–1591. 19 indexed citations
3.
Lawrence, Mitchell G., Laura H. Porter, David Pook, et al.. (2021). CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics. 20(11). 2140–2150. 17 indexed citations
4.
Kusnadi, Eric, et al.. (2021). Regulation of gene expression via translational buffering. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1869(1). 119140–119140. 29 indexed citations
5.
Oertlin, Christian, Julie Lorent, Carl Murie, et al.. (2019). Generally applicable transcriptome-wide analysis of translation using anota2seq. Nucleic Acids Research. 47(12). e70–e70. 49 indexed citations
6.
Porter, Laura H., Mitchell G. Lawrence, Shahneen Sandhu, et al.. (2019). PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer. 2 indexed citations
7.
Pearson, Helen, Jason Li, Valérie S. Méniel, et al.. (2018). Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discovery. 8(6). 764–779. 78 indexed citations
8.
Rebello, Richard J., Richard B. Pearson, Ross D. Hannan, & Luc Furic. (2017). Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes. 8(2). 71–71. 85 indexed citations
9.
Lindqvist, Lisa, Kristofferson Tandoc, Ivan Topisirović, & Luc Furic. (2017). Cross-talk between protein synthesis, energy metabolism and autophagy in cancer. Current Opinion in Genetics & Development. 48. 104–111. 91 indexed citations
10.
Rebello, Richard J., Eric Kusnadi, Donald P. Cameron, et al.. (2016). The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research. 22(22). 5539–5552. 61 indexed citations
11.
Rebello, Richard J., Eric Kusnadi, Donald P. Cameron, et al.. (2016). The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer. European Journal of Cancer. 61. S167–S167. 10 indexed citations
12.
Gandin, Valentina, Laìa Masvidal, Marie Cargnello, et al.. (2016). mTORC1 and CK2 coordinate ternary and eIF4F complex assembly. Nature Communications. 7(1). 11127–11127. 73 indexed citations
13.
Robichaud, Nathaniel, Sonia V. del Rincón, Bonnie Huor, et al.. (2014). Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene. 34(16). 2032–2042. 205 indexed citations
14.
Lawrence, Mitchell G., Renea A. Taylor, Camden Lo, et al.. (2012). Estrogen Receptor β Activation Impairs Prostatic Regeneration by Inducing Apoptosis in Murine and Human Stem/Progenitor Enriched Cell Populations. PLoS ONE. 7(7). e40732–e40732. 32 indexed citations
15.
Furic, Luc, Liwei Rong, Ola Larsson, et al.. (2010). eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences. 107(32). 14134–14139. 398 indexed citations
16.
Petroulakis, Emmanuel, Armen Parsyan, Ryan J.O. Dowling, et al.. (2009). p53-Dependent Translational Control of Senescence and Transformation via 4E-BPs. Cancer Cell. 16(5). 439–446. 93 indexed citations
17.
18.
Kim, Yoon Ki, Luc Furic, Marc Parisien, et al.. (2007). Staufen1 regulates diverse classes of mammalian transcripts. The EMBO Journal. 26(11). 2670–2681. 168 indexed citations
19.
Furic, Luc & Luc DesGroseillers. (2005). La régulation post-transcriptionnelle de l’expression génique : un autre rôle de la protéine Staufen1. médecine/sciences. 21(6-7). 571–573.
20.
Bélanger, Guy, Marie Vandromme, Laurent Schaeffer, et al.. (2003). Localization of the RNA‐binding proteins Staufen1 and Staufen2 at the mammalian neuromuscular junction. Journal of Neurochemistry. 86(3). 669–677. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew C. Hsieh Breakdown of academic impact, for papers by Jasper Mullenders Breakdown of academic impact, for papers by Gong‐Hong Wei Breakdown of academic impact, for papers by Christian Touriol Breakdown of academic impact, for papers by Jakob Lovén Breakdown of academic impact, for papers by Joseph M. Amann Breakdown of academic impact, for papers by David Tulasne Breakdown of academic impact, for papers by Markus E. Diefenbacher Breakdown of academic impact, for papers by Jianfei Qi Breakdown of academic impact, for papers by Long‐Yuan Li
Rankless by CCL
2026